载脂蛋白B在心血管疾病风险预测中的应用进展

Progress in the application of apolipoprotein B in cardiovascular disease risk prediction

心血管疾病(CVD)是我国居民非传染性疾病死亡的首要原因,且其患病率逐年升高,已成为人类健康的头号“杀手”。研究表明,载脂蛋白B(ApoB)作为CVD发生风险的危险因素,在评估CVD进展方面具有一定的优势,它能直接测量低密度脂蛋白(LDL)粒子数,且检测不受禁食限制,可作为筛查、诊断和管理CVD的主要测量指标。故该文对ApoB的特点、ApoB评估CVD风险的SWOT分析、降低ApoB水平的方法及其在CVD风险预测中的作用做一综述,以期更好地了解ApoB在CVD风险评估中的临床应用,有助于及早发现、预防和治疗CVD。

Cardiovascular disease(CVD)is the leading cause of non communicable disease mortality in China,and its prevalence rate is increasing year by year,which has become the number one"killer"of human health.Studies have shown that apolipoprotein B(ApoB),as a risk factor for CVD,has certain advantages in assessing the progression of CVD.It can directly measure the number of low-density lipoprotein(LDL)particles,and the test is not subject to fasting,so it can be used as the main measurement index for screening,diagnosis and management of CVD.Therefore,this paper provides a review of the characteristics of ApoB,SWOT analysis of ApoB for CVD risk assessment,methods to reduce ApoB level and its role in CVD risk prediction,with a view to contributing to the clinical application of ApoB in CVD risk assessment,and better assisting in the early detection,prevention,and treatment of cardiovascular disease.